Planning Future Clinical Trials for Machado-Joseph Disease

Area of Science:

• Neuroscience
• Genetics
• Clinical Trials Methodology

Background:

• Spinocerebellar ataxia type 3/Machado-Joseph disease (SCA3/MJD) is a neurodegenerative disorder caused by ATXN3 gene CAG repeat expansion.
• Limited evidence exists for disease-modifying and symptomatic treatments in SCA3/MJD patients from randomized clinical trials (RCTs).

Purpose of the Study:

• To discuss critical methodological challenges in designing future RCTs for SCA3/MJD.
• To outline optimal study designs, outcome measures, and trial parameters for both disease-modifying and symptomatic therapies.
• To address considerations for testing new drugs when effective treatments are available and the role of presymptomatic individuals in trials.

Main Methods:

• Detailed discussion of methodological issues for planning SCA3/MJD RCTs.
• Evaluation of study designs, including placebo-controlled RCTs for disease-modifying therapies.
• Consideration of clinical scales like the Scale for the Assessment and Rating of Ataxia (SARA) and quantitative ataxia scales as primary outcomes.
• Discussion of eligibility criteria, randomization, sample size, trial duration, and analysis types.

Main Results:

• Placebo-controlled RCTs are optimal for disease-modifying therapies; alternative designs may suit some symptomatic treatments.
• The SARA scale is the preferred instrument for assessing treatment efficacy against ataxia in SCA3/MJD.
• Quantitative ataxia scales offer greater sensitivity for early efficacy signals in phase 2 RCTs.
• Multicenter trials are necessary for disease-modifying therapies due to large sample size requirements.

Conclusions:

• There is a critical need for well-designed RCTs to address various therapeutic aims in SCA3/MJD care.
• Development and validation of surrogate markers are essential for multiple drug classes.
• Engaging at-risk or presymptomatic individuals in trials is crucial for advancing treatment research in SCA3/MJD.